Witryna(1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a fundamental role in both early and advanced stages. Currently, in advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based … http://yuxiqbs.cqvip.com/Qikan/Article/Detail?id=7001186496
IMPOWER Consulting LinkedIn
Witryna25 cze 2024 · IMpower133 is a phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of atezolizumab in … WitrynaIn the IMpower 133 and CASPIAN trials, almost half of patients who exhibited evidence of disease progression were reported to receive a subsequent therapy (51.7% in the AEP group; 42.0% in the DEP group, and a pooled estimated of 51.6% in … crystal casey facebook
Recent developments in the treatment of small cell lung cancer
WitrynaSmall-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The... Witrynatherapy for ES-SCLC demonstrated this combination was well tolerated [15]. In summary, these two studies provided strong evidence to support the use of immune checkpoint blockade in ES-SCLC. However, questions remain regarding whether anti-PD-1/L1 in combination with other immune check-point inhibitors could further enhance the … Witryna10 wrz 2024 · IMpower131 is a randomized Phase III trial of atezolizumab + chemotherapy vs chemotherapy alone as first-line therapy in Stage IV squamous NSCLC, which is the most advanced form of the disease. The five year survival rate for those diagnosed with stage IV lung cancer is less than 10 percent. crystal caseworks display case